The answer is unclear because biologics do not have a repository similar to the FDA’s Orange Book to list the patents that confer exclusivity to marketed drugs.
The US healthcare law passed a few months ago establishes an Orange-Book-like mechanism for newly approved biologics (see #msg-48581353, section (8)(H)(3) about 1/3 of the way down), so investors will eventually have a way to answer the kinds of questions you asked without the need for time-consuming research.
Speaking of Remicade…does anyone here care to handicap the upcoming arbitration between MRK and JNJ? The outcome is highly consequential because Remicade is a very big-selling drug outside the US.
I’ve predicted that JNJ will prevail, unless the case is settled prior to a decision by the arbitration panel (#msg-38036981, #msg-41045971).